TY - JOUR
T1 - Regret of treatment decision and its association with disease-specific quality of life following prostate cancer treatment
AU - Diefenbach, Michael A.
AU - Mohamed, Nihal E.
N1 - Funding Information:
Keywords: Prostate cancer, Regret of treatment decision, Treatment modality, Quality of life. Supported by Grants CA6136-04 and CA06927 for the Behavioral Core Research Facility at Fox Chase Cancer Center from the National Cancer Institute, Grant PADOH ME-98155 from the Commonwealth of Pennsylvania, and Grant DAMD 17-1-1-006 from the Department of Defense. The authors are indebted to the referring physicians in the Departments of Radiation Oncology and Urology of Fox Chase Cancer Center, Philadelphia, PA for their support of the study. Correspondence to: Michael A. Diefenbach Mount Sinai School of Medicine One Gustave L. Levy Place, Box 1272 New York, NY 10029-6574 USA e-mail: [email protected]
PY - 2007/9
Y1 - 2007/9
N2 - We examined decisional regret among prostate cancer patients and its association with disease-specific quality of life. Patients (N = 793) completed questionnaires at diagnosis, at 6 months, and 12 months thereafter. Although levels of decisional regret were low, regret increased significantly between 6 and 12 months after diagnosis. The increase was substantial for patients treated with prostatectomy compared to patients treated with external beam radiation or brachytherapy. Cross-sectional, significant, and positive associations among regret, activity limitation attributed to urinary dysfunction, and bother with sexual and urinary dysfunction emerged. Longitudinally, the change in the level of regret was significantly associated with treatment modality and with the change in bother with sexual dysfunction over the first 6 months after diagnosis. Extensive discussions about disease-specific quality of life should be included when physicians counsel patients about treatment options.
AB - We examined decisional regret among prostate cancer patients and its association with disease-specific quality of life. Patients (N = 793) completed questionnaires at diagnosis, at 6 months, and 12 months thereafter. Although levels of decisional regret were low, regret increased significantly between 6 and 12 months after diagnosis. The increase was substantial for patients treated with prostatectomy compared to patients treated with external beam radiation or brachytherapy. Cross-sectional, significant, and positive associations among regret, activity limitation attributed to urinary dysfunction, and bother with sexual and urinary dysfunction emerged. Longitudinally, the change in the level of regret was significantly associated with treatment modality and with the change in bother with sexual dysfunction over the first 6 months after diagnosis. Extensive discussions about disease-specific quality of life should be included when physicians counsel patients about treatment options.
KW - Prostate cancer
KW - Quality of life
KW - Regret of treatment decision
KW - Treatment modality
UR - http://www.scopus.com/inward/record.url?scp=34548823824&partnerID=8YFLogxK
U2 - 10.1080/07357900701359460
DO - 10.1080/07357900701359460
M3 - Article
C2 - 17882657
AN - SCOPUS:34548823824
SN - 0735-7907
VL - 25
SP - 449
EP - 457
JO - Cancer Investigation
JF - Cancer Investigation
IS - 6
ER -